Pharmalink AB Strengthens Senior Management Team

               Pharmalink AB Strengthens Senior Management Team

  PR Newswire

  STOCKHOLM, October 29, 2012

STOCKHOLM, October 29, 2012 /PRNewswire/ --

     Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek
              Poszepczynski as Director of Business Development

Pharmalink AB, a Swedish specialty pharma company, today announces it has
appointed Dr. Heather Cook as Director of Regulatory Affairs and Mr. Marek
Poszepczynski as Director of Business Development.

Dr. Cook brings to Pharmalink over 15 years of experience within the
pharmaceutical industry, with a proven track record in global regulatory
affairs and clinical development. Prior to joining Pharmalink, Dr. Cook was
Head of Department for Regulatory Development Projects at H. Lundbeck A/S. She
was also Global Regulatory Affairs Director, Oncology for Astra Zeneca and
held a number of other senior roles including Scientific Director for
Neuroscience and Infection. She has worked in the UK, Canada, and Denmark and
currently resides in Stockholm. Dr. Cook is also Partner, Pharma and Biotech
R&D consultant at PharmaView Consulting HB. She has a PhD in Zoology from the
University of Toronto and is completing an MBA at Stockholm School of

Marek Poszepczynski joins Pharmalink after a career spanning 10 years and
combining financial and business development experience. Before joining
Pharmalink, Mr. Poszepczynski was lead equity analyst at Handelsbanken
covering European and Swedish biotechnology stocks. Prior to Handelsbanken,
Mr. Poszepczynski was Vice President of Business Development at Karolinska
Development, where he carried out a wide variety of tasks including
streamlining the company's business operations as well as taking part in M&A,
licensing and fund raising negotiations. Mr. Poszepczynski spent six years at
BioVitrum AB where he was Director of Corporate Development, and part of the
in-and-out licensing deals team of the company's R&D portfolio. Mr.
Poszepczynski holds a Master of Industrial Engineering and Business Management
from KTH Royal Institute of Technology, Stockholm.

Pharmalink's Managing Director Johan Häggblad said, "These appointments add
significant talent and new experience to Pharmalink's management team as the
Company continues to drive forward its late stage clinical development
programs for Nefecon® and Busulipo™ and actively seeks new product
opportunities. It is a measure of our reputation that such high caliber
executives have joined us and I look forward to working with Heather and Marek
through what is an exciting stage of development."

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high value
products for niche indications. Pharmalink draws on its extensive experience
of pharmaceutical development and marketing and the excellence of medical
science in Sweden to identify and progress products that address significant
unmet medical needs. With a successful history in pharmaceutical sales and
marketing, and highly experienced, dynamic management team, Pharmalink is
currently focused on the development of valuable, de-risked projects using a
repurposing and reformulation strategy. It has two late-stage clinical phase
products under development, Nefecon® and Busulipo™, having successfully
divested its Xepol® product in 2010. Pharmalink is actively seeking
opportunities to acquire or in-licence product opportunities in niche and
hospital care indications. Visit for further

For further information, please contact:

Pharmalink AB: Johan Häggblad, Managing Director, +46(0)70-668-0644 Email:

Citigate Dewe Rogerson:Chris Gardner/Nina Enegren, +44-207-638-9571
Press spacebar to pause and continue. Press esc to stop.